Atlassian (NASDAQ:TEAM – Get Free Report) had its price target lifted by KeyCorp from $185.00 to $235.00 in a note issued to investors on Monday, Marketbeat.com reports. The firm presently has an “overweight” rating on the technology company’s stock. KeyCorp’s price objective would indicate a potential upside of 6.28% from the company’s current price. TEAM […]

Seagate Technology (NASDAQ:STX – Get Free Report) had its price objective lifted by stock analysts at Morgan Stanley from $1,187.00 to $1,200.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the data storage provider’s stock. Morgan Stanley’s target price would suggest a potential upside of 77.55% from […]

Schrodinger (NASDAQ:SDGR – Get Free Report) had its target price hoisted by investment analysts at UBS Group from $19.00 to $21.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. UBS Group’s price objective points to a potential downside of 9.17% from the stock’s current price. […]

Victory Capital (NASDAQ:VCTR – Get Free Report) had its target price lifted by equities research analysts at JPMorgan Chase & Co. from $101.00 to $120.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside […]

Absci (NASDAQ:ABSI – Get Free Report) had its price objective upped by analysts at JPMorgan Chase & Co. from $14.00 to $15.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 55.68% from the […]

BeOne Medicines (NASDAQ:ONC – Get Free Report) had its target price hoisted by equities researchers at Royal Bank Of Canada from $450.00 to $459.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target would indicate […]

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target increased by stock analysts at Truist Financial from $150.00 to $158.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s target price would suggest a potential upside of […]